Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

doi:10.1186/1471-2407-9-1

BMC Cancer

Volume 9

Viewing options:

Associated material:

Readers' comments (1)
Pre-publication history
PubMed record

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Kavanagh DO
Chambers G
O' Grady L
Barry KM
Waldron RP
Bennani F
Eustace PW
Tobbia I

on PubMed

Kavanagh DO
Chambers G
O' Grady L
Barry KM
Waldron RP
Bennani F
Eustace PW
Tobbia I
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Nominate for award

Post to:

Comments(1)

Targeting EGFR, HER2 and VEGF

Michael Hölling (23 January 2009) Roche Pharma AG

Dear Sir, my first comment is just a technical one, as for the time being the provisional pdf of the article is not accessible. Secondly, in the abstract the monoclonal antibody (MAB)Bevacizumab is erroneously described as targeting the human epidermal growth factor receptor (EGFR), while in fact it targets the vascular endothelial growth factor (VEGF) (but not its receptor). The MAB targeting the EGFR is named Cetuximab. Yours faithfully Michael Hölling

Competing interests

Roche: employee

top

Comments(1)

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Targeting EGFR, HER2 and VEGF

Have something to say? Post a comment on this article!